Proteacel is creating a new standard for gene transfection. The company’s core patented technology is Perforation Optimization and Repair Enhancement (PORE™), a non-viral gene delivery product licensed exclusively and worldwide to Proteacel. PORE™ demonstrates a superior methodology by surpassing the current industry standards for gene delivery and cell viability, the two most pivotal outcomes of the transfection process. The PORE™ technology is scalable, allows for complex transfections and maintains long-term growth potential of genetically modified cells.

Proteacel is primed to offer transfection services and custom transfected cells to the academic, biotechnology and pharmaceutical communities. By growing relationships within these markets and by collaborating with investigators, Proteacel will develop and co-develop products for drug discovery, toxicology, cell differentiation and cell based therapies. With PORE™, the highest quality transfection tool on the market, Proteacel is poised to develop proprietary methods and strategies that will enable the scientific community to enhance its operations for the pursuit of discovery and the creation of new innovative therapies.